Overview

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).

Phase:

Phase 3

Details

Lead Sponsor:

Cidara Therapeutics Inc.

Treatments:

Caspofungin
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Echinocandins
Enzyme Inhibitors
Fluconazole
Molecular Mechanisms of Pharmacological Action
Rezafungin